Cadila settles litigation with Celgene over patents for the anti-cancer drug Revlimid
Cadila Healthcare and its subsidiary Zydus Pharmaceuticals Inc. have reached a settlement with Celgene Corporation on 24 March 2021. This settlement was done over the patents for the anti–cancer drug Revlimid.
Per this agreement, both parties will file consent judgments with the US district court for New Jersey. This will prohibit Zydus Cadila from marketing the generic version of the drug before the patent expires, except as provided for in the settlement. [3]
About Revlimid
Revlimid is used for the treatment of multiple myeloma and myelodysplastic syndrome. Its patent expires in March 2022. US–based firm Celgene Corporation is a wholly–owned subsidiary of Bristol Meyers Squibb ( BMS ). In 2020, BMS had garnered over $ 12 billion in sales from Revlimid, making it the largest drug in its sales in 2020.
Cadila is apparently the fifth company to settle litigation with Celgene over the patent. The other companies that were previously involved were Cipla, Natco Pharma, and Dr. Reddy’s Laboratories. A few pharma firms are still locked in legal battles with this US–based firm. These include Aurobindo Pharma, Hetero Drugs, Mylan, Sun Pharma, and Lupin.
Cipla had resolved its case with Celgene in December 2020. Based on the agreement, Cipla would get a license to manufacture and sell a certain volume of the generic version in the US after March 2022. Apart from this, until 31 January 2026, the volume of generic Revlimid sold by Cipla could not exceed the agreed–upon percentages. After this period, Cipla can manufacture and sell an unlimited quantity of the drug.
- Pharma News – 23.01.2023 to 29.01.2023
Mankind Pharma invests in Actimed Therapeutics to support the latter’s development of treatment for cancer cachexia. On 23 January 2023, […] - Lupin issues nationwide recall of Clobetasol propionate cream.
On 4 February 2023, Lupin announced the recall of Clobetasol propionate cream over quality issues. As per the USFDA [1], the pharma […] - Global Pharma Healthcare recalls Artificial Tears Lubricant eye drops.
The USFDA[1] has revealed that Global Pharma Healthcare recalls all the batches of artificial tears lubricant eye drops from the […] - Milestones in Cancer Research and DiscoveryCancer research and discovery is the process of uncovering new information about cancer and how it can be treated. This […]
- OAI notice for Torrent Pharma Indrad facility
USFDA issues OAI notice for Torrent Pharma’s Indrad facility in Gujarat.In response to this notice, Torrent Pharma has clarified that […] - Cancer Cachexia: Mankind Pharma’s association with Actimed Therapeutics
On 23 January 2023, Mankind Pharma announced its move to invest in the UK-based clinical-stage specialty pharma company Actimed Therapeutics. […]